BioInvent to Supply Critical Antibodies for Orbus Medical Technology's Innovative Genous Bio-engineered Surface
BioInvent to Supply Critical Antibodies for Orbus Medical Technology's Innovative Genous Bio-engineered Surface Lund, Sweden and Fort Lauderdale, FL, USA: BioInvent International AB (SAX:BINV) and Orbus Medical Technologies, Inc. announced today the signing of an agreement for the supply of cGMP quality antibodies for clinical evaluation stents coated with the Genous Bio-engineered Surface. This innovative coating is applied to a stent for the prevention of thrombosis (blood clotting) and the reduction of restenosis (reblockage) following coronary angioplasty to open clogged arteries.